Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with TACE for hepatocellular carcinoma
2004-004963-32Phase 2Completed
- Sponsor
- Markus Peck-Radosavljevic
- Start
- Jun 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in hepatocellular carcinoma (HCC), sponsored by Markus Peck-Radosavljevic. Primary endpoints: Patients without tumor progression after 3 TACE cycles, Number of TACE cycles for recurrent tumor within 1 year and 1 more. Started Jun 2005; status: completed.
02
Drugs
bevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2004-004963-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004963-32.